Trade Novartis - CHF - NOVN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.40 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.023611% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | -0.020833% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | CHF | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | Switzerland | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Novartis AG ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 78.05 |
| Open* | 78.55 |
| 1-Year Change* | 0.26% |
| Day's Range* | 78.55 - 79.65 |
| 52 wk Range | 72.84-88.42 |
| Average Volume (10 days) | 4.80M |
| Average Volume (3 months) | 88.08M |
| Market Cap | 189.09B |
| P/E Ratio | 27.27 |
| Shares Outstanding | 2.12B |
| Revenue | 47.24B |
| EPS | 2.89 |
| Dividend (Yield %) | 4.08893 |
| Beta | 0.98 |
| Next Earnings Date | Apr 25, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 2, 2023 | 78.05 | -2.05 | -2.56% | 80.10 | 80.40 | 77.95 |
| Feb 1, 2023 | 80.25 | -2.10 | -2.55% | 82.35 | 82.35 | 79.80 |
| Jan 31, 2023 | 82.40 | -0.70 | -0.84% | 83.10 | 83.10 | 82.25 |
| Jan 30, 2023 | 83.05 | 0.45 | 0.54% | 82.60 | 83.30 | 82.30 |
| Jan 27, 2023 | 82.50 | 0.10 | 0.12% | 82.40 | 82.75 | 81.85 |
| Jan 26, 2023 | 82.75 | -1.25 | -1.49% | 84.00 | 84.15 | 82.60 |
| Jan 25, 2023 | 85.05 | 0.30 | 0.35% | 84.75 | 85.10 | 84.70 |
| Jan 24, 2023 | 84.85 | 0.15 | 0.18% | 84.70 | 85.00 | 84.35 |
| Jan 23, 2023 | 85.05 | 0.65 | 0.77% | 84.40 | 85.10 | 84.10 |
| Jan 20, 2023 | 84.30 | -0.25 | -0.30% | 84.55 | 84.80 | 84.30 |
| Jan 19, 2023 | 84.30 | -0.30 | -0.35% | 84.60 | 85.30 | 84.20 |
| Jan 18, 2023 | 84.40 | -0.70 | -0.82% | 85.10 | 85.20 | 84.10 |
| Jan 17, 2023 | 85.35 | -0.45 | -0.52% | 85.80 | 86.00 | 85.05 |
| Jan 16, 2023 | 85.95 | 1.80 | 2.14% | 84.15 | 85.95 | 84.15 |
| Jan 13, 2023 | 84.40 | 0.75 | 0.90% | 83.65 | 84.60 | 83.65 |
| Jan 12, 2023 | 84.05 | -0.05 | -0.06% | 84.10 | 84.65 | 83.40 |
| Jan 11, 2023 | 83.80 | 0.30 | 0.36% | 83.50 | 84.35 | 83.05 |
| Jan 10, 2023 | 83.50 | -0.35 | -0.42% | 83.85 | 84.30 | 82.65 |
| Jan 9, 2023 | 85.25 | -0.20 | -0.23% | 85.45 | 85.75 | 84.90 |
| Jan 6, 2023 | 85.60 | 1.40 | 1.66% | 84.20 | 85.75 | 84.20 |
Novartis - CHF Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total revenue | 49386 | 43361 | 46017 | 48624 | 49898 | 52877 |
| Revenue | 49386 | 43361 | 46017 | 48624 | 49898 | 52877 |
| Cost of Revenue, Total | 17338 | 13416 | 13555 | 13930 | 14400 | 15435 |
| Gross Profit | 32048 | 29945 | 32462 | 34694 | 35498 | 37442 |
| Total Operating Expense | 41111 | 34658 | 31824 | 39538 | 39746 | 41188 |
| Selling/General/Admin. Expenses, Total | 14111 | 12468 | 13690 | 14319 | 14093 | 14815 |
| Research & Development | 8402 | 7808 | 8154 | 8386 | 8484 | 9041 |
| Depreciation / Amortization | 43 | 187 | 179 | 50 | 64 | 109 |
| Unusual Expense (Income) | 911 | 395 | -4309 | 2284 | 2503 | 1173 |
| Other Operating Expenses, Total | 306 | 384 | 549 | 607 | 538 | 653 |
| Operating Income | 8275 | 8703 | 14193 | 9086 | 10152 | 11689 |
| Interest Income (Expense), Net Non-Operating | -440 | 418 | -5 | -36 | -146 | 14628 |
| Other, Net | -18 | -19 | -93 | -110 | -128 | -180 |
| Net Income Before Taxes | 7817 | 9102 | 14095 | 8940 | 9878 | 26137 |
| Net Income After Taxes | 6698 | 7499 | 12800 | 7147 | 8071 | 24018 |
| Minority Interest | 14 | 0 | -3 | -5 | 1 | 3 |
| Net Income Before Extra. Items | 6712 | 7499 | 12797 | 7142 | 8072 | 24021 |
| Net Income | 6712 | 7703 | 12611 | 11732 | 8072 | 24021 |
| Income Available to Common Excl. Extra. Items | 6712 | 7499 | 12797 | 7142 | 8072 | 24021 |
| Income Available to Common Incl. Extra. Items | 6712 | 7703 | 12611 | 11732 | 8072 | 24021 |
| Dilution Adjustment | 0 | |||||
| Diluted Net Income | 6712 | 7703 | 12611 | 11732 | 8072 | 24021 |
| Diluted Weighted Average Shares | 2400 | 2371 | 2344 | 2319 | 2296 | 2260 |
| Diluted EPS Excluding Extraordinary Items | 2.79667 | 3.1628 | 5.45947 | 3.07978 | 3.51568 | 10.6288 |
| Dividends per Share - Common Stock Primary Issue | 2.70191 | 2.87386 | 2.90402 | 3.04815 | 3.38945 | 3.19907 |
| Diluted Normalized EPS | 3.12191 | 3.30006 | 3.79006 | 3.86715 | 4.40641 | 11.1183 |
| Total Extraordinary Items | 204 | -186 | 4590 | |||
| Interest Expense (Income) - Net Operating | 6 | -38 | -336 | -38 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Total revenue | 12694 | 13294 | 13367 | 13522 | 12814 |
| Revenue | 12694 | 13294 | 13367 | 13522 | 12814 |
| Cost of Revenue, Total | 3833 | 3754 | 3848 | 4000 | 3755 |
| Gross Profit | 8861 | 9540 | 9519 | 9522 | 9059 |
| Total Operating Expense | 10279 | 9815 | 10134 | 10960 | 9962 |
| Selling/General/Admin. Expenses, Total | 3520 | 3710 | 3601 | 3984 | 3498 |
| Research & Development | 2127 | 2284 | 2261 | 2369 | 2256 |
| Depreciation / Amortization | 27 | 27 | 25 | 30 | 35 |
| Interest Expense (Income) - Net Operating | -101 | 60 | -9 | 12 | 102 |
| Unusual Expense (Income) | 690 | -136 | 312 | 307 | 193 |
| Other Operating Expenses, Total | 183 | 116 | 96 | 258 | 123 |
| Operating Income | 2415 | 3479 | 3233 | 2562 | 2852 |
| Interest Income (Expense), Net Non-Operating | 54 | 38 | 21 | 14415 | -203 |
| Other, Net | -19 | -11 | -24 | -26 | 20 |
| Net Income Before Taxes | 2450 | 3506 | 3230 | 16951 | 2669 |
| Net Income After Taxes | 2059 | 2895 | 2758 | 16306 | 2219 |
| Minority Interest | 0 | 1 | 0 | 2 | 3 |
| Net Income Before Extra. Items | 2059 | 2896 | 2758 | 16308 | 2222 |
| Net Income | 2059 | 2896 | 2758 | 16308 | 2222 |
| Income Available to Common Excl. Extra. Items | 2059 | 2896 | 2758 | 16308 | 2222 |
| Income Available to Common Incl. Extra. Items | 2059 | 2896 | 2758 | 16308 | 2222 |
| Diluted Net Income | 2059 | 2896 | 2758 | 16308 | 2222 |
| Diluted Weighted Average Shares | 2265 | 2243 | 2254 | 2257 | 2237 |
| Diluted EPS Excluding Extraordinary Items | 0.90905 | 1.29113 | 1.2236 | 7.22552 | 0.99329 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 3.39838 | 0 |
| Diluted Normalized EPS | 1.16507 | 1.24106 | 1.3418 | 7.35637 | 1.06502 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 24931 | 28208 | 35563 | 29504 | 29673 | 45718 |
| Cash and Short Term Investments | 7546 | 9347 | 15718 | 11234 | 11293 | 28113 |
| Cash | 1912 | 2970 | 3121 | 3247 | 3750 | 3396 |
| Cash & Equivalents | 5095 | 5890 | 10150 | 7865 | 5908 | 9011 |
| Short Term Investments | 539 | 487 | 2447 | 122 | 1635 | 15706 |
| Total Receivables, Net | 10208 | 11101 | 11036 | 10337 | 10036 | 9621 |
| Accounts Receivable - Trade, Net | 8203 | 8601 | 8739 | 8301 | 8217 | 8005 |
| Total Inventory | 6255 | 6867 | 6956 | 5982 | 7131 | 6666 |
| Prepaid Expenses | 692 | 756 | 812 | 898 | 943 | 1102 |
| Other Current Assets, Total | 230 | 137 | 1041 | 1053 | 270 | 216 |
| Total Assets | 130124 | 133079 | 145563 | 118370 | 127778 | 131795 |
| Property/Plant/Equipment, Total - Net | 15641 | 16464 | 15696 | 13746 | 13939 | 13106 |
| Property/Plant/Equipment, Total - Gross | 31296 | 34010 | 34028 | 28676 | 29894 | 28708 |
| Accumulated Depreciation, Total | -15655 | -17546 | -18332 | -14930 | -15955 | -15602 |
| Goodwill, Net | 30980 | 31750 | 35294 | 26524 | 29999 | 29595 |
| Intangibles, Net | 31340 | 29997 | 38719 | 28787 | 36809 | 34182 |
| Long Term Investments | 15400 | 16645 | 9789 | 10538 | 11611 | 2268 |
| Note Receivable - Long Term | 1100 | 968 | 908 | 624 | 922 | 973 |
| Other Long Term Assets, Total | 10732 | 9047 | 9594 | 8647 | 4825 | 5953 |
| Total Current Liabilities | 22209 | 23403 | 29607 | 28264 | 33059 | 30208 |
| Accounts Payable | 4873 | 5169 | 5556 | 5424 | 5403 | 5553 |
| Accrued Expenses | 4169 | 4811 | 5105 | 5058 | 5336 | 5100 |
| Notes Payable/Short Term Debt | 5611 | 4842 | 6430 | 4844 | 7319 | 3606 |
| Current Port. of LT Debt/Capital Leases | 178 | 359 | 3190 | 2248 | 2558 | 2896 |
| Other Current Liabilities, Total | 7378 | 8222 | 9326 | 10690 | 12443 | 13053 |
| Total Liabilities | 55292 | 58911 | 66949 | 62896 | 71180 | 64140 |
| Total Long Term Debt | 17897 | 23224 | 22470 | 22056 | 27978 | 24523 |
| Long Term Debt | 17897 | 23224 | 22470 | 20353 | 26259 | 22902 |
| Deferred Income Tax | 6657 | 5168 | 7475 | 5867 | 3141 | 3070 |
| Minority Interest | 59 | 59 | 78 | 77 | 68 | 167 |
| Other Liabilities, Total | 8470 | 7057 | 7319 | 6632 | 6934 | 6172 |
| Total Equity | 74832 | 74168 | 78614 | 55474 | 56598 | 67655 |
| Common Stock | 972 | 969 | 944 | 936 | 913 | 901 |
| Retained Earnings (Accumulated Deficit) | 81148 | 77639 | 82191 | 59274 | 57157 | 70989 |
| Treasury Stock - Common | -76 | -100 | -69 | -80 | -53 | -48 |
| Unrealized Gain (Loss) | 348 | 386 | 206 | |||
| Other Equity, Total | -7560 | -4726 | -4658 | -4656 | -1419 | -4187 |
| Total Liabilities & Shareholders’ Equity | 130124 | 133079 | 145563 | 118370 | 127778 | 131795 |
| Total Common Shares Outstanding | 2374.06 | 2317.46 | 2311.17 | 2265.01 | 2256.82 | 2234.94 |
| Capital Lease Obligations | 1703 | 1719 | 1621 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 22198 | 23808 | 26253 | 45718 | 37236 |
| Cash and Short Term Investments | 4077 | 5356 | 8162 | 28329 | 18814 |
| Cash & Equivalents | 3801 | 5117 | 7211 | 12407 | 13852 |
| Short Term Investments | 276 | 239 | 951 | 15922 | 4962 |
| Total Receivables, Net | 8481 | 8654 | 8632 | 8283 | 8678 |
| Accounts Receivable - Trade, Net | 8265 | 8400 | 8377 | 8005 | 8409 |
| Total Inventory | 6997 | 7111 | 6885 | 6666 | 6997 |
| Other Current Assets, Total | 2643 | 2687 | 2574 | 2440 | 2747 |
| Total Assets | 121752 | 124015 | 121209 | 131795 | 125218 |
| Property/Plant/Equipment, Total - Net | 13204 | 13344 | 13157 | 13106 | 12861 |
| Goodwill, Net | 29590 | 29766 | 29572 | 29595 | 29636 |
| Intangibles, Net | 35377 | 34818 | 33951 | 34182 | 34853 |
| Long Term Investments | 11628 | 12014 | 12347 | 3241 | 2906 |
| Other Long Term Assets, Total | 9755 | 10265 | 5929 | 5953 | 7726 |
| Total Current Liabilities | 30160 | 29633 | 29880 | 30208 | 29807 |
| Accounts Payable | 5040 | 4811 | 4665 | 5553 | 5083 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 10400 | 9278 | 9528 | 6502 | 6902 |
| Other Current Liabilities, Total | 14720 | 15544 | 15687 | 18153 | 17822 |
| Total Liabilities | 71229 | 69973 | 64438 | 64140 | 63678 |
| Total Long Term Debt | 27399 | 26491 | 24715 | 24523 | 24373 |
| Long Term Debt | 25747 | 24828 | 23101 | 22902 | 22796 |
| Capital Lease Obligations | 1652 | 1663 | 1614 | 1621 | 1577 |
| Deferred Income Tax | 7393 | 7472 | 3349 | 3070 | 3384 |
| Minority Interest | 66 | 86 | 166 | 167 | 164 |
| Other Liabilities, Total | 6211 | 6291 | 6328 | 6172 | 5950 |
| Total Equity | 50523 | 54042 | 56771 | 67655 | 61540 |
| Common Stock | 913 | 913 | 901 | 901 | 901 |
| Retained Earnings (Accumulated Deficit) | 49670 | 53194 | 55917 | 66802 | 60699 |
| Treasury Stock - Common | -60 | -65 | -47 | -48 | -60 |
| Total Liabilities & Shareholders’ Equity | 121752 | 124015 | 121209 | 131795 | 125218 |
| Total Common Shares Outstanding | 2245.09 | 2236.74 | 2237.09 | 2234.94 | 2212.58 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Net income/Starting Line | 6698 | 7499 | 12800 | 7147 | 8071 | 24018 |
| Cash From Operating Activities | 11475 | 12621 | 14272 | 13625 | 13650 | 15071 |
| Cash From Operating Activities | 1591 | 1460 | 1783 | 1852 | 2088 | 1807 |
| Amortization | 4452 | 3276 | 3428 | 3974 | 4376 | 4306 |
| Non-Cash Items | 2239 | 1983 | -2315 | 3369 | 3842 | -11714 |
| Cash Taxes Paid | 2111 | 1487 | 1506 | 1876 | 1833 | 2342 |
| Cash Interest Paid | 723 | 697 | 816 | 793 | 703 | 664 |
| Changes in Working Capital | -3505 | -1597 | -1424 | -2717 | -4727 | -3346 |
| Cash From Investing Activities | -3441 | -3119 | -5591 | -2226 | -13182 | 4208 |
| Capital Expenditures | -2879 | -2294 | -2648 | -2257 | -2585 | -2971 |
| Other Investing Cash Flow Items, Total | -562 | -825 | -2943 | 31 | -10597 | 7179 |
| Cash From Financing Activities | -5314 | -7733 | -4244 | -13627 | -2208 | -16264 |
| Financing Cash Flow Items | 1 | -101 | -119 | 3307 | -199 | 94 |
| Total Cash Dividends Paid | -6475 | -6495 | -6966 | -6645 | -6987 | -7368 |
| Issuance (Retirement) of Stock, Net | -895 | -5238 | -1336 | -5332 | -2094 | -3004 |
| Issuance (Retirement) of Debt, Net | 2055 | 4101 | 4177 | -4957 | 7072 | -5986 |
| Foreign Exchange Effects | -387 | 84 | -26 | 69 | 286 | -266 |
| Net Change in Cash | 2333 | 1853 | 4411 | -2159 | -1454 | 2749 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 2059 | 4954 | 7712 | 24018 | 2219 |
| Cash From Operating Activities | 2130 | 6262 | 11187 | 15071 | 1649 |
| Cash From Operating Activities | 514 | 893 | 1287 | 1807 | 392 |
| Amortization | 1183 | 2248 | 3307 | 4306 | 1013 |
| Non-Cash Items | 386 | 803 | 1732 | -11714 | 918 |
| Cash Taxes Paid | 735 | 1144 | 1459 | 2342 | 633 |
| Cash Interest Paid | 112 | 301 | 458 | 664 | 110 |
| Changes in Working Capital | -2012 | -2636 | -2851 | -3346 | -2893 |
| Cash From Investing Activities | 780 | 877 | -355 | 4208 | 9365 |
| Capital Expenditures | -858 | -1455 | -1994 | -2971 | -859 |
| Other Investing Cash Flow Items, Total | 1638 | 2332 | 1639 | 7179 | 10224 |
| Cash From Financing Activities | -8540 | -11479 | -13013 | -16264 | -9528 |
| Financing Cash Flow Items | -35 | 77 | 87 | 94 | 22 |
| Total Cash Dividends Paid | -7368 | -7368 | -7368 | -7368 | -7506 |
| Issuance (Retirement) of Stock, Net | -1892 | -2572 | -2856 | -3004 | -2448 |
| Issuance (Retirement) of Debt, Net | 755 | -1616 | -2876 | -5986 | 404 |
| Foreign Exchange Effects | -227 | -201 | -266 | -266 | -41 |
| Net Change in Cash | -5857 | -4541 | -2447 | 2749 | 1445 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.068 | 121820582 | 660676 | 2021-12-31 | LOW |
| Sandoz Family | Other Insider Investor | 3.7082 | 89135960 | 0 | 2021-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.4876 | 59794919 | -679553 | 2022-12-31 | LOW |
| UBS Asset Management (Switzerland) | Investment Advisor | 2.3185 | 55730682 | -1033720 | 2021-12-31 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.2522 | 54136583 | 54136583 | 2022-12-31 | LOW |
| Credit Suisse Asset Management | Investment Advisor/Hedge Fund | 2.0806 | 50012984 | -174106 | 2021-12-31 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.0521 | 49325778 | -15385 | 2022-12-31 | LOW |
| Zürcher Kantonalbank (Asset Management) | Bank and Trust | 1.1159 | 26822930 | 181109 | 2022-12-31 | LOW |
| Capital Research Global Investors | Investment Advisor | 0.8782 | 21108834 | -7644157 | 2022-12-31 | LOW |
| Dodge & Cox | Investment Advisor/Hedge Fund | 0.862 | 20719470 | -327400 | 2022-12-31 | LOW |
| BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.8066 | 19388239 | -155972 | 2022-12-31 | LOW |
| Artisan Partners Limited Partnership | Investment Advisor | 0.6534 | 15705529 | -519288 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5919 | 14227704 | 2 | 2023-01-31 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.5016 | 12057792 | -73 | 2022-10-31 | LOW |
| DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.4992 | 12000477 | -5607 | 2022-12-31 | LOW |
| California Public Employees' Retirement System | Pension Fund | 0.3896 | 9365057 | -577585 | 2021-06-30 | LOW |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.3272 | 7864627 | 71357 | 2022-12-31 | LOW |
| MFS Investment Management | Investment Advisor/Hedge Fund | 0.3037 | 7301275 | -26066 | 2022-12-31 | LOW |
| Nuveen LLC | Pension Fund | 0.2963 | 7122790 | -21014 | 2022-12-31 | LOW |
| Fidelity International | Investment Advisor | 0.2547 | 6122301 | -47790 | 2022-12-31 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group +485000+
Traders
65000+
Active clients monthly
$48000000+
Monthly investing volume
$28000000+
Try now Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Leverage
20:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Novartis - CHF Company profile
Novartis AG (NVS) is a global pharmaceutical company. Founded in 1996 through a merger of Ciba-Geigy and Sandoz, Novartis is headquartered in Basel, Switzerland. The firm has two divisions: Innovative Medicines and Sandoz.
Innovative Medicines offer prescription medicines and create treatments in areas of respiratory, ophthalmology, neuroscience, immunology, hepatology, dermatology, cardiovascular, renal and metabolism.
Sandoz develops, manufactures and markets generic pharmaceuticals and biosimilars. Sandoz products include: Adakveo (crizanlizumab), Afinitor Disperz/Votubia (everolimus) and Arzerra (ofatumumab) for Oncology; and Aimovig (erenumab) for neuroscience.
In 2020, in response to the pandemic, the company collaborated with Molecular Partners to develop ensovibep, a DARPin therapeutic candidate designed for potential use against Covid-19.
The company’s shares have been listed on the New York Stock Exchange (NYSE) since 2000. Novartis AG stock is traded under the ticker symbol NVS. You can track live NVS share value and price history at Capital.com.
| Industry: | Pharmaceuticals (NEC) |
Lichtstrasse 35
BASEL
BASEL-STADT 4056
CH
Income Statement
- Annual
- Quarterly
News
S&P 500 & DAX 40 Forecast for the Week Ahead
S&P 500 builds higher after Fed meeting, DAX 40 runs into resistance
16:30, 3 February 2023
FX Weekly Outlook: USD, GBP/USD, USD/JPY Analysis
USD, GBP/USD, USD/JPY forecasts for the week ahead.
15:56, 3 February 2023
GBP/USD drops below 1.23 as BOE comments suggest possible end of rate hikes
Despite increasing rates by 50bps at their February meeting, the messaging from the BOE suggests a dovish tilt an the possible end of rate hikes.
15:37, 2 February 2023
Gold latest: XAU/USD rallies on Fed meeting as traders eye Friday’s jobs data
Gold buyers take advantage of risk on sentiment as they eye Friday's NFP data to assess the likelihood of a soft landing
11:48, 2 February 2023
British Pound (GBP) Outlook: GBP/USD, EUR/GBP Ahead of BoE Rate Decision
Bank of England remains a dovish hiker. GBP at risk of another dovish twist
15:13, 1 February 2023People also watch
Still looking for a broker you can trust?
Join the 480.000+ traders worldwide that chose to trade with Capital.com